Jury convicts SAC fund manager for insider trading

The highly publicized insider trading case against SAC Capital Advisors trader Mathew Martoma has finally come to a conclusion--at least for now. A jury found him guilty in the case in which SAC was said to have reaped $275 million in profits but trading on tips from a clinical researcher that much-hyped Alzheimer's hopeful from Elan ($ELN) and Wyeth, was about to flunk out of clinical development, The New York Times reports. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.